AU2002333079A1 - Individualization of therapy with anxiolitics - Google Patents
Individualization of therapy with anxioliticsInfo
- Publication number
- AU2002333079A1 AU2002333079A1 AU2002333079A AU2002333079A AU2002333079A1 AU 2002333079 A1 AU2002333079 A1 AU 2002333079A1 AU 2002333079 A AU2002333079 A AU 2002333079A AU 2002333079 A AU2002333079 A AU 2002333079A AU 2002333079 A1 AU2002333079 A1 AU 2002333079A1
- Authority
- AU
- Australia
- Prior art keywords
- anxiolitics
- individualization
- therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/948—Sedatives, e.g. cannabinoids, barbiturates
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Pathology (AREA)
- Anesthesiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Composite Materials (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials Engineering (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/072,611 US20030091975A1 (en) | 2001-02-09 | 2002-02-08 | Multiple determinants for metabolic phenotypes |
| US10/072,611 | 2002-02-08 | ||
| US10/100,272 US20030175210A1 (en) | 2001-03-14 | 2002-03-14 | Individualization of therapy with anxiolitics |
| US10/100,272 | 2002-03-14 | ||
| PCT/CA2002/001512 WO2003067257A1 (en) | 2002-02-08 | 2002-10-08 | Individualization of therapy with anxiolitics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2002333079A1 true AU2002333079A1 (en) | 2003-09-02 |
Family
ID=27736814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002333079A Abandoned AU2002333079A1 (en) | 2002-02-08 | 2002-10-08 | Individualization of therapy with anxiolitics |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU2002333079A1 (en) |
| WO (1) | WO2003067257A1 (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2167330A1 (en) * | 1996-01-31 | 1997-08-01 | Xanthus Life Sciences, Inc. | Elisa kit for the rapid determination of n-acetyltransferase (nat2) phenotypes |
| AU3138800A (en) * | 1999-03-15 | 2000-10-04 | Brian Leyland-Jones | Elisa kit for the determination of metabolic phenotypes |
-
2002
- 2002-10-08 AU AU2002333079A patent/AU2002333079A1/en not_active Abandoned
- 2002-10-08 WO PCT/CA2002/001512 patent/WO2003067257A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003067257A1 (en) | 2003-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003224725A1 (en) | Hiv therapeutic | |
| AU2003280262A1 (en) | Individualization of therapy with anticoagulants | |
| AU2002244568A1 (en) | Individualization of therapy with antipsychotics | |
| AU2003247005A1 (en) | Therapy combination | |
| AU2003249722A1 (en) | Therapeutic amides | |
| AU2003245794A1 (en) | Glycosaminoglycan-dnase combination therapy | |
| AU2003215150A1 (en) | Therapeutic compounds | |
| AU2002302223A1 (en) | Individualization of therapy with analgesics | |
| AU2002335667A1 (en) | Modified reoviral therapy | |
| AU2003219580A1 (en) | Novel therapeutical use of byakangelicin | |
| AU2002244575A1 (en) | Individualization of therapy with antidepressants | |
| AU2002349225A1 (en) | Individualization of therapy with antiviral agents | |
| AU2003900495A0 (en) | Aroylhydrazone derivatives and therapeutic uses thereof | |
| AU2003285079A1 (en) | Neurostimulation therapy manipulation | |
| AU2003231803A1 (en) | Treatment of cancer with mefloquire | |
| AU2002953223A0 (en) | Novel therapeutic molecules and uses thereof | |
| AU2003240052A1 (en) | Il-11 derivatives and therapeutic uses thereof | |
| AU2002257411A1 (en) | Individualization of therapy with antineoplastic agents | |
| AU2002350344A1 (en) | Individualization of therapy with antihistamines | |
| AU2002257451A1 (en) | Individualization of therapy with antibiotic agents | |
| AU2002333079A1 (en) | Individualization of therapy with anxiolitics | |
| AU2003231937A1 (en) | Therapeutic methods | |
| AU2002342488A1 (en) | Individualization of therapy with anesthetics | |
| AU2002953516A0 (en) | Genetic therapy and genetic modification | |
| AU2003287840A1 (en) | Arylthioetherpyrimidine and aryloxyetherpyrimidine derivatives and their therapeutic uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |